Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
Verified date | December 2023 |
Source | Georgetown University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX. We hypothesize that the addition of Eryaspase to FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) will be safe and demonstrate preliminary signs of efficacy in patients with advanced pancreatic cancer. Safety assessments include adverse events, physical examination abnormalities, vital signs, and clinical laboratory tests (including blood chemistry, hematology, and coagulation panel).
Status | Active, not recruiting |
Enrollment | 19 |
Est. completion date | July 2024 |
Est. primary completion date | January 18, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient must be able to understand and willing to sign an IRB approved written informed consent document. - Patient must have histologically or cytologically confirmed pancreatic adenocarcinoma, which is locally advanced, unresectable, or metastatic. - Patient must have received no previous surgery, chemotherapy, radiotherapy or investigational therapy for the treatment of locally advanced or metastatic disease. - If a patient has had adjuvant/neoadjuvant therapy for localized disease, tumor recurrence or disease progression must have occurred no sooner than 6 months after completing the last dose of the aforementioned therapies. - Patient must have radiographically measurable disease according to RECIST 1.1 - Patient must be > 18 years of age. - Patient must have a life expectancy of >= 3 months. - Patient must have an ECOG performance status = 1. - Patient must have normal bone marrow and organ function as defined below: - Absolute neutrophil count >=1,500/mcl - Platelets >=100,000/mcl - Hemoglobin >=9.0 g/dL - Serum Albumin >=3.0 g/dL - Creatinine should be below the upper limit of normal OR Creatinine clearance (eGFR) >=60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal - Plasma antithrombin III >= 65%, fibrinogen >= 150 mg/dL, international normalized ratio (INR) = 1.5, and partial thromboplastin time (PTT) = institutional ULN. - Total bilirubin = 1.5x institutional ULN - Patients who have had a stent placed for biliary obstruction can be included in the study. - Female subject of childbearing potential must have a negative urine or serum pregnancy test. - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. - Male subjects with a female partner of childbearing potential must agree to use two adequate methods or a barrier method plus a method of contraception Exclusion Criteria: - Evidence of neuroendocrine tumor, duodenal adenocarcinoma, or ampullary adenocarcinoma. - History of other malignancy = 3 years ago, with the exception of basal cell or squamous cell carcinoma of the skin, which were treated with local resection only or carcinoma in situ of the cervix of ductal carcinoma in situ. - Receiving any other investigational agents 28 days prior to the screening process. - Patient with evidence of brain metastases. Such patients must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to asparaginase, 5FU, oxaliplatin, or irinotecan. - Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection , symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, any clinically active malabsorption syndrome, inflammatory bowel disease, any condition that increases the risk of severe irinotecan gastrointestinal toxicity, or psychiatric illness/social situations that would limit compliance with study requirements - Has an active autoimmune disease, or a documented history of autoimmune disease or syndrome that requires steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. - Has had an allogeneic tissue/solid organ transplant. - Has received or will receive a live vaccine within 30 days prior to the first administration of study medication. Seasonal flu vaccines that do not contain live virus are permitted - Has known active Hepatitis B or C. - Patient is pregnant and/or breastfeeding. - Known to be HIV-positive on combination antiretroviral. |
Country | Name | City | State |
---|---|---|---|
United States | Georgetown Lombardi Comprehensive Cancer Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Georgetown University | ERYtech Pharma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Grade 3 or 4 adverse events | The number and percentage of all subjects who experience adverse events (AEs), serious adverse events (SAEs), or abnormal laboratory results according to NCI CTCAE Version 5.0, that occur after Cycle 1, Day 1 will be reported. | 12 months | |
Secondary | Objective Response Rate | Estimated | 2 years | |
Secondary | progression-free survival (PFS) | Summarized | 2 years | |
Secondary | overall survival (OS) | Summarized | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04935359 -
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
|
Phase 3 | |
Active, not recruiting |
NCT05095064 -
Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
|
||
Active, not recruiting |
NCT05039177 -
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT04888312 -
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT04390763 -
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
|
Phase 2 | |
Not yet recruiting |
NCT06206876 -
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Completed |
NCT02501902 -
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
|
Phase 1 | |
Active, not recruiting |
NCT04581343 -
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients
|
Phase 1 | |
Completed |
NCT02558894 -
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
|
Phase 2 | |
Terminated |
NCT02732938 -
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
|
Phase 2 | |
Recruiting |
NCT05472259 -
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
|
Phase 2 | |
Recruiting |
NCT06445062 -
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT02600949 -
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
|
Phase 1 | |
Recruiting |
NCT05630183 -
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02583477 -
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT04329949 -
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
Terminated |
NCT02101021 -
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
Suspended |
NCT05685602 -
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06398587 -
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 2 |